Global Active Pharmaceutical Ingredients (API) and High Potency API (HPAPI) Industry Outlook to 2016 - Shifting Focus Towards Biotechnology

Global Active Pharmaceutical Ingredients (API) and High Potency API (HPAPI) Industry Outlook to 2016 - Shifting Focus Towards Biotechnology


  • Products Id :- AM203
  • |
  • Pages: 178
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

The report titled “Global Active Pharmaceutical Ingredients (API) and High Potency API (HPAPI) Industry Outlook to 2016 - Shifting Focus Towards Biotechnology” provides a comprehensive analysis of the market size of the global API industry based on the regions such as North America, Asia-Pacific and Western Europe, market segmentation by generic and innovator API and on the basis of revenue earned from pharmaceutical raw materials for own needs and from commodity bulk drugs sold. The global API market is also segmented on the basis of synthetic and biotechnology based APIs. An analysis of the market size of global HPAPI industry is provided on the basis of regions such as North America, Europe and Asia-Pacific and the market segmentation by revenue from innovator and generic HPAPI.

Global

The global API market in 2011 valued at USD ~million as compared to USD ~ million in 2005 with an appreciation for the generic and innovator APIs throughout the globe. The market in 2011 inclined by ~% of which Asia-Pacific witnessed a strong growth of ~% followed by Western Europe with a growth rate of ~% during the year. The robust growth rate can be attributed to the patent expiry of several innovator APIs in the recent years thereby driving the market for generic APIs in almost all the regions in the world.

The global HPAPI industry worldwide has showcased a favorable growth trend in the recent past other than the setback in the year 2009 which was the result of the global economic turbulence. The industry was valued at USD ~ million in 2011 and has proclaimed to be a niche yet fastest growing segment of the API industry. The global API market which has traditionally been dominated by small molecule drugs or the synthetic molecules has been gradually witnessing a shift towards the biopharmaceuticals. 

North America
North America has the most advanced and highly developed healthcare system with the largest pharmaceutical spending in the historical years. The country is the world’s largest API market since many years with a share of ~% across the globe in 2011. The US was the largest market for APIs with generic APIs contributing ~% to the total revenue generated by the North America commodity bulk drugs market in 2011 and innovator APIs contributing ~% to the market during the year. Biologics and generics are the fastest growing segments of this industry.

Biotechnology-derived APIs in the region which were valued at USD ~ million in 2011 are a growing constituent of the pharmaceutical industry.
The HPAPI market in North America has been a highly developed and regulated pharmaceutical market with 44.8% share in the overall market for HPAPI in the world. The region has been cited as the most sought after in the research and development of high potency compounds over the years.

Asia Pacific

Asia-Pacific is the second largest API market in the world with a contribution of ~% to the global commodity bulk drugs market. The region has shown outstanding performance in the last few years and has emerged as the fastest growing pharmaceutical industry in the world. It has recorded the highest growth rates in the API segment among the other continents across the globe It was recorded that around ~% of the APIs used for manufacturing pharmaceutical products in the US and Western Europe were imported from Asia-Pacific countries in 2011

The low costs coupled with skilled manpower have made Indian firms highly competitive suppliers of the API manufacturing, research and development and outsourcing activities. It was observed that the country’s contribution in the Asia-Pacific API market has increased significantly from ~% in 2005 to ~% in 2011. The commodity bulk drugs market size of China was valued at USD ~ million in 2011 as compared to USD ~ million in 2005.

The HPAPI market in Asia-Pacific is expected to grow at a CAGR of 17% from 2012-2016 and will reach USD 1,937.1 million by 2016.

Europe

The Western Europe API market has experienced several ups and down over the past few years with the emergence of Asia-Pacific countries in the global API production. Western Europe has emerged as the third largest market for the APIs with a share of ~% in the global API market in 2011 as compared to ~% share in 2005.

Italy is the largest market for commodity bulk drugs in Western Europe with sales of USD ~ million in 2011 as compared to USD ~million in 2005. It was perceived that Italy held the leading position as the exporter of APIs to the US in 2011. The country exported USD ~ million generic APIs to the US in 2005.

The HPAPI industry in Europe is held by few of the major countries such as the UK, Germany and France. The market in the UK is the largest contributor to the overall revenue of the HPAPI in Europe. The France HPAPI industry has witnessed a strong growth rate in the HPAPI market in Europe. In 2011, the market recorded revenue worth USD ~ million thereby growing by 14.7% during the year on account of rise in the demand for oncology drugs in the country.

Key Topics Covered in the Report

  • The market size of the Global API Industry and its segments such as generic and innovator API, pharmaceutical raw materials for own needs and commodity bulk drugs sold, 2005-2011 and synthetic and biotech based API market share, 2011.
  • The market size of HPAPI industry and segments such as generic and innovator HPAPI.
  • The market size of the global API industry in the three regions such as North America, Western Europe and Asia-Pacific, 2005-2011.
  • The market size of the global HPAPI industry in the three regions such as North America, Europe and Asia-Pacific, 2005-2011.
  • Market segmentation of global API industry in regions such as Asia Pacific, Western Europe and North America on the basis of revenue of generic and innovator API, 2005-2011.
  • Trends and Development of the Global API Industry.
  • Competitive landscape of the major players of API in the world US, 2009 & 2011.
  • Company profile of the major producers of API in the world.
  • Future outlook and projections of API and HPAPI Industry on the basis of total revenue and segment revenue from innovator and generic for API and HPAPI, 2012-2016.
  • Macroeconomics and industry factors including Research and development expenditure on pharmaceuticals, number of inpatient discharges healthcare expenditure per capita and ageing population, 2005-2011.


Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

1. Global Active Pharmaceutical Ingredients (API) Industry Introduction

2. Global API Market Size by Revenue, 2005-2011

3. Global API Market Segmentation
3.1. By Generic API and Innovator API, 2005-2011
3.2. By Pharmaceutical Raw Materials for Own Needs and Commodity Bulk Drugs/ Sales by a third party API, 2005-2011
3.3. Commodity Bulk Drugs By Geography, 2005-2011
3.4. By Synthetic and Biotech Product Type Route, 2011

4. Global API Industry Regulations
General Overview

5. Global API Market Trends and Developments

Shifting Preference towards Biotechnology Based API
Increasing Backward Integration by Drug Formulation companies in India
Expanding Generic API Market

6. Market Share of Major Players in Global API Industry, 2009 and 2011

7. Global API Industry Future Outlook and Projections
7.1. By Geography, 2012-2016
7.2. By Generic and Innovator API, 2012-2016
7.3. By Pharmaceutical raw material for own needs and Commodity Bulk Drugs, 2012-2016
7.4. By Synthetic and Biotech Product Type Route, 2012-2016
7.5. Cause and Effect Relationship between Industry Factors and Global API Industry Prospects

8. North America API Industry
8.1. North America Commodity Bulk Drugs Market Size, 2005-2011
8.2. North America Commodity Bulk Drugs Market Segmentation
8.2.1. By Generic and Innovator API, 2005-2011
8.2.2. By Biotech Based API Segment, 2005-2011
8.2.3. By Geography, 2005-2011
8.2.3.1. The US Commodity Bulk Drugs Market Size, 2005-2011
8.2.3.1.1. By Generic and Branded API Segments, 2005-2011
8.2.3.1.2. By Biotech Based API Segment, 2005-2011
8.2.3.2. The US Commodity Bulk Drugs Market Future Outlook and Projections, 2012-2016
8.2.3.3. Canada Commodity Bulk Drugs Market Size, 2005-2011
8.2.3.4. Canada Commodity Bulk Drugs Market Future Outlook and Projections, 2012-2016
8.3. North America Commodity Bulk Drugs Market Future Outlook and Projections, 2012-2016

9. Asia-Pacific API Industry
9.1. Asia-Pacific Commodity Bulk Drugs Market Size, 2005-2011
9.2. Asia-Pacific Commodity Bulk Drugs Market Segmentation
9.2.1. By Generic and Innovator API, 2005-2011
9.2.2. By Biotech Based API Segment, 2005-2011
9.2.3. By Geography, 2005-2011
9.2.3.1. China Commodity Bulk Drugs Market Size, 2005-2011
9.2.3.1.1. By Generic and Innovator API Segments, 2005-2011
9.2.3.2. China Commodity Bulk Drugs Market Future Outlook and Projections, 2012-2016
9.2.3.3. India Commodity Bulk Drugs Market Size, 2005-2011
9.2.3.3.1. By Generic and Innovator API Segments, 2005-2011
9.2.3.4. India Commodity Bulk Drugs Market Future Outlook and Projections, 2012-2016
9.3. Asia-Pacific Commodity Bulk Drugs Market Future Outlook and Projections, 2012-2016

10. Western Europe API Industry
10.1. Western Europe Commodity Bulk Drugs Market Size, 2005-2011
10.2. Western Europe Commodity Bulk Drugs Market Segmentation
10.2.1. By Generic and Innovator API, 2005-2011
10.2.2. By Geography, 2005-2011
10.2.2.1. Italy Commodity Bulk Drugs Market Size, 2005-2011
10.2.2.1.1. By Generic and Innovator API Segments, 2005-2011
10.2.2.2. Italy Commodity Bulk Drugs Market Future Outllok and Projections, 2012-2016
10.2.2.3. Spain Commodity Bulk Drugs Market Size, 2005-2011
10.2.2.3.1. By Generic and Innovator API Segments, 2005-2011
10.2.2.4. Spain Commodity Bulk Drugs Market Future Outlook and Projections, 2012-2016
10.3. Western Europe Commodity Bulk Drugs Market Future Outlook and Projections, 2012-2016

11. Global API Major Players Company Profile
11.1. Pfizer Inc.
11.1.1. Company Overview
11.1.2. Business Strategy
11.2. GlaxoSmithKline Pharmaceuticals Ltd.
11.2.1. Company Overview
11.2.2. Business Strategy
11.3. Roche
11.3.1. Company Overview
11.3.2. Business Strategy
11.4. AstraZeneca International
11.4.1. Company Overview
11.4.2. Business Strategy
11.5. Novartis
11.5.1. Company Overview
11.5.2. Business Strategy

12. Global High Potency Active Pharmaceutical Ingredients (HPAPI) Industry Introduction

13. Global HPAPI Market Size by Revenue, 2005-2011

14. Global HPAPI Market Segmentation
14.1. By Generic API and Innovator API, 2005-2011
14.2. HPAPI By Geography, 2005-2011

15. Global HPAPI Industry Future Outlook and Projections
15.1. By Geography, 2012-2016
15.2. By Generic and Innovator HPAPI, 2012-2016

16. North America HPAPI Industry
16.1. North America HPAPI Market Size By Value, 2005-2011
16.1.1. By The US and Canada
16.2. North America HPAPI Market Future Outlook and Projections, 2012-2016
16.2.1. By The US and Canada

17. Europe HPAPI Industry
17.1. Europe HPAPI Market Size By Value, 2005-2011
17.1.1. By The UK, Germany, France and Others
17.2. Europe HPAPI Market Future Outlook and Projections, 2012-2016
17.2.1. By The UK, Germany, France and Others

18. Asia-Pacific HPAPI Industry
18.1. Asia-Pacific HPAPI Industry Introduction
18.2. Asia- Pacific Market Size, 2005-2011
18.2.1. By Japan, India, China and Others
18.3. Asia- Pacific HPAPI Market Future Outlook and Projections, 2012-2016
18.3.1. By Japan, China, India and Others

19. Global Macro-Economic Factors of API and HPAPI Industry
19.1. Global Pharmaceutical Sales, 2005-2011
19.2. The US
19.2.1. Inpatient Admissions & Outpatients Visits, 2005- 2010
19.2.2. Prescription Drug Price Index, 2005-2010
19.2.3. Ageing Population in the US, 2008-2011
19.2.4. The US Pharmaceutical Sales, 2009-2011
19.2.5. Healthcare Expenditure Per Capita, 2005-2011
19.3. Canada
19.3.1. Ageing Population, 2008-2011
19.3.2. Healthcare Expenditure Per Capita, 2005-2011
19.4. India
19.4.1. Healthcare Expenditure, FY’2006-FY’2016
19.4.2. Ageing Population, 2008-2011
19.4.3. Research & Development Expenditure on Pharmaceuticals, 2005-2010
19.5. China
19.5.1. Ageing Population, 2008-2011
19.5.2. Healthcare Expenditure, 2006-2011
19.6. Japan
19.6.1. Ageing Population, 2008-2011
19.6.2. Healthcare Expenditure Per Capita, 2005-2011
19.7. Western Europe Pharmaceutical Sales, 2009-2011
19.8. Italy
19.8.1. Total In-Patients Discharges, 2005-2011
19.8.2. Healthcare Expenditure Per Capita, 2005-2011
19.8.3. Ageing Population 2008-2011
19.9. Spain
19.9.1. Healthcare Expenditure Per Capita, 2005-2011
19.9.2. Ageing Population, 2008-2011
19.10. Germany
19.10.1. Total In-Patients Discharges, 2006-2011
19.10.2. Healthcare Expenditure Per Capita, 2005-2011
19.10.3. Research and development Expenditure on Pharmcaeuticals, 2005-2011
19.10.4. Ageing Population, 2008-2011
19.11. The UK
19.11.1. Total In-Patients Discharges, 2005-2011
19.11.2. Healthcare Expenditure Per Capita, 2005-2011
19.11.3. Research and Development Expenditure on Pharmceuticals, 2005-2011
19.11.4. Ageing Population, 2008-2011
19.12. France
19.12.1. Total In-Patients Discharges, 2005-2011
19.12.2. Healthcare Expenditure Per Capita, 2005-2011
19.12.3. Ageing Population, 2008-2011

20. Appendix
20.1. Market Definition
20.2. Abbreviations
20.3. Research Methodology
Data Collection Methods
Approach
Variables (Dependent and Independent)
Multi Factor Based Sensitivity Model
Final Conclusion
20.4. Disclaimer 

Figure 1: Global API Market Size on the Basis of Revenue in USD Million, 2005-2011

Figure 2: Global API Market Segmentation on the Basis of Revenue from Generic and Innovator API in USD Million, 2005-2011

Figure 3: Global API Market Segmentation by Generic and Innovator API on the Basis of Revenue in Percentage (%), 2005-2011

Figure 4: Global API Market Segmentation on the Basis of Revenue from Pharmaceutical Raw Material for Own Needs and Commodity Bulk Drugs Sales in USD Million, 2005-2011

Figure 5: Global Commodity Bulk Drugs Market Segmentation by North America, Western Europe, Asia-Pacific and Others on the Basis of Revenue in Percentage(%), 2005-2011

Figure 6: Global API Revenue by Product Type Based on Synthesis Route in Percentage (%), 2011

Figure 7: Global Biotech Based API on the Basis of Revenue in USD Million, 2005-2011

Figure 8: Market Share of Major Players in Global API Industry in Percentage (%), 2009

Figure 9: Market Share of Major Players in Global API Industry in Percentage (%), 2011

Figure 10: Global API Industry Projections on the Basis of Revenue in USD Million, 2012-2016

Figure 11: Global Commodity Bulk Drugs Market Future Projections by North America, Western Europe, Asia-Pacific and Others on the Basis of Revenue in Percentage (%), 2012-2016

Figure 12: Global Commodity Bulk Drugs Market Future Projections by North America, Asia-Pacific, Western Europe and Others on the Basis of Revenue in USD Million, 2012-2016

Figure 13: Global API Industry Projections on the Basis of Revenue from Generic and Innovator API in USD Million, 2012-2016

Figure 14: Global API Industry Projections on the Basis of Revenue from Pharmaceutical Raw Materials for Own Needs and Commodity Bulk Drugs Sales in USD Million, 2012-2016

Figure 15: Global API Revenue by Product Type Based on Synthesis Route in Percentage (%), 2011

Figure 16: Global Biotech Based API Market Projections on the Basis of Revenue in USD Million, 2012-2016

Figure 17 : North America Commodity Bulk Drugs Market Size on the Basis of Revenue in USD Million, 2005-2011

Figure 18: North America API Industry Market Segmentation on the Basis on Revenue from Generic API and Innovator API in USD Million, 2005-2011

Figure 19: North America Commodity Bulk Drugs Market Segmentation on the Basis of Revenue from Biotech Based API in USD Million, 2005-2011

Figure 20: The US Commodity Bulk Drugs Market Size on the Basis of Revenue in USD Million, 2005-2011

Figure 21: The US Commodity Bulk Drug Market Segmentation on the Basis of Revenue from Generic and Innovator API in USD Million, 2005-2011

Figure 22: The US Commodity Bulk Drugs Market Segmentation on the Basis of Revenue from Biotech Based API Segment in USD Million, 2005-2011

Figure 23: The US Commodity Bulk Drugs Market Projections on the Basis of Revenue in USD Million, 2012-2016

Figure 24: The US Commodity Bulk Drugs Future Projections by Market Segmentation on the Basis of Revenue from Generic API and Innovator API, 2012-2016

Figure 25: Canada Commodity Bulk Drugs Market Size on the Basis of Revenue in USD Million, 2005-2011

Figure 26: Canada Commodity Bulk Drugs Market Projections on the Basis of Revenue in USD Million, 2012-2016

Figure 27: North America Commodity Bulk Drugs Market Future Projections on the Basis of Revenue in USD Million, 2012-2016

Figure 28: North America Commodity Bulk Drugs Market Future Projections by Market Segmentation on the Basis of Revenue from Generic and Innovator API, 2012-2016

Figure 29: Asia-Pacific Commodity Bulk Drugs Market Size on the Basis of Revenue in USD Million, 2005-2011

Figure 30: Asia-Pacific Commodity Bulk Drugs Market Segmentation on the Basis of Revenue from Generic and Innovator API, 2005-2011

Figure 31: Asia-Pacific Commodity Bulk Drugs Market Segmentation on the Basis of Revenue from Biotech Based API in USD Million, 2005-2011

Figure 32: China Commodity Bulk Drugs Market Size on the Basis of Revenue in USD Million, 2005-2011

Figure 33: China Commodity Bulk Drugs Market Segmentation on the Basis of Revenue from Generic and Innovator API in USD Million, 2005-2011

Figure 34: China Commodity Bulk Drugs Market Projections on the Basis of Revenue in USD Million, 2012-2016

Figure 35: China Commodity Bulk Drug Market Projections by Market Segmentation on the Basis of Revenue in USD Million, 2012-2016

Figure 36: India Commodity Bulk Drugs Market Size on the Basis of Revenue in USD Million, 2005-2011

Figure 37: India Commodity Bulk Drugs Market Segmentation on the Basis of Revenue from Generic and Innovator API in USD Million, 2005-2011

Figure 38: India Commodity Bulk Drugs Market Projections on the Basis of Revenue in USD Million, 2012-2016

Figure 39: India Commodity Bulk Drug Market Projections by Market Segmentation on the Basis of Revenue from Generic and Innovator API in USD Million, 2012-2016

Figure 40: Asia-Pacific API Industry Projects on the Basis of Revenue in USD Million, 2012-2016

Figure 41: Asia-Pacific Commodity Bulk Drugs Market Future Projections by Market Segmentation on the Basis of Revenue from Generic and Innovator API, 2012-2016

Figure 42: Western Europe Commodity Bulk Drugs Market Size on the Basis of Revenue in USD Million, 2005-2011

Figure 43: Western Europe Commodity Bulk Drugs Market Segmentation on the Basis of Revenue from Generic and Innovator API in USD Million, 2005-2011

Figure 44: Italy Commodity Bulk Drugs Market Size on the Basis of Revenue in USD Million, 2005-2011

Figure 45: Italy Commodity Bulk Drugs Market Segmentation on the Basis of Revenue from Generic and Innovator API in USD Million, 2005-2011

Figure 46: Italy Commodity Bulk Drugs Market Future Projections on the Basis of Revenue in USD Million, 2012-2016

Figure 47: Italy Commodity Bulk Drugs Market Future Projections by Market Segmentation on the Basis of Revenue from Generic and Innovator API, 2012-2016

Figure 48: Spain Commodity Bulk Drugs Market Size on the Basis of Revenue in USD Million, 2005-2011

Figure 49: Spain Commodity Bulk Drugs Market Segmentation on the Basis of Revenue from Generic and Innovator API in USD Million, 2005-2011

Figure 50: Spain Commodity Bulk Drugs Market Future Projections on the Basis of Revenue in USD Million, 2012-2016

Figure 51: Spain Commodity Bulk Drugs Market Future Projections by Market Segmentation on the Basis of Revenue from Generic and Innovator API in USD Million, 2012-2016

Figure 52: Western Europe Commodity Bulk Drugs Market Future Projection on the Basis of Revenue in USD Million, 2012-2016

Figure 53: Western Europe Commodity Bulk Drugs Market Future Projections by Market Segmentation on the Basis of Revenue from Generic and Innovator API in USD Million, 2012-2016

Figure 54: Global HPAPI Market Size on the Basis of Revenue in USD Million, 2005-2011

Figure 55: Global HPAPI Marker Segmentation on the Basis of Revenue from Generic and Innovator HPAPI in USD Million, 2005-2011

Figure 56: Global HPAPI Market Segmentation by North America, Europe and Asia-Pacific and Others on the Basis of Revenue in Percentage (%), 2005-2011

Figure 57: Global HPAPI Industry Projections on the Basis of Revenue in USD Million, 2012-2016

Figure 58: Global HPAPI Market Future Projections by North America, Europe, Asia-Pacific and Others on the Basis of Revenue in Percentage(%), 2012-2016

Figure 59: Global HPAPI Market Segmentation Projections on the Basis of Revenue from Generic and Innovator HPAPIs, 2012-2016

Figure 60: North America HPAPI Market Size on the Basis of Revenue in USD Million, 2005-2011

Figure 61: North America HPAPI Market Segmentation by the US and Canada on the Basis of Revenue in Percentage (%), 2005-2011

Figure 62: North America HPAPI Market Size Projections on the Basis of Revenue in USD Million, 2012-2016

Figure 63: Europe HPAPI Market Size on the Basis of Revenue in USD Million, 2005-2011

Figure 64: Europe HPAPI Market Size by the UK, Germany, France and Others on the Basis of Revenue in Percentage (%), 2005-2011

Figure 65: Europe HPAPI Market Projections by Revenue in USD Million, 2012-2016

Figure 66: Asia-Pacific HPAPI Market Size on the Basis of Revenue in USD Million, 2005-2011

Figure 67: Asia-Pacific HPAPI Market Size by Japan, China, India and Others on the Basis of Revenue in Percentage (%), 2005-2011

Figure 68: Asia-Pacific HPAPI Market Projections on the Basis of Revenue in USD Million, 2012-2016

Figure 69: Global Pharmaceutical Sales in USD Million, 2005-2011

Figure 70: Inpatient Admissions in Community Hospitals in the US, in Million, 2005-2010

Figure 71: Outpatient Visits in Community Hospitals in the US, in Million, 2005-2010

Figure 72: The US Prescription Drug Price Index, 2005-2015

Figure 73: The US Ageing Population in Million, 2008-2011

Figure 74: The US Pharmaceutical Sales in USD Million, 2009-2011

Figure 75: The US Healthcare Expenditure Per Capita, 2005-2011

Figure 76: Canada Ageing Population in Millions, 2008-2011

Figure 77: Canada Healthcare Expenditure Per Capita in USD, 2005-2011

Figure 78: The Indian Health Expenditure in USD Million, FY’06-FY’16

Figure 79: India Ageing Population, 2008-2011

Figure 80: Research and Development Expenditure on Pharmaceuticals in USD Million, 2005-2010

Figure 81: China Ageing Population, 2008-2011

Figure 82: Healthcare Expenditure in China, 2006-2011

Figure 83: Japan Ageing Population, 2008-2011

Figure 84: Japan Healthcare Expenditure Per Capita in USD, 2005-2011

Figure 85: Western Europe Pharmaceutical Sales in USD Million, 2009-2011

Figure 86: Italy In-Patients Discharges by Hospitals, 2005-2011

Figure 87: Italy Healthcare Expenditure Per Capita in US, 2005-2011

Figure 88: Italy Ageing Population, 2008-2011

Figure 89: Spain Healthcare Expenditure Per Capita in USD, 2005-2011

Figure 90: Spain Ageing Population, 2008-2011

Figure 91: Germany In-Patient Discharges by Hospitals, 2005-2011

Figure 92: Germany Healthcare Expenditure Per Capita in USD, 2005-2011

Figure 93: Research and Development Expenditure on Pharmaceuticals in Germany in USD Million, 2005-2011

Figure 94: Germany Ageing Population, 2008-2011

Figure 95: The UK In-Patient Discharges by Hospitals, 2005-2011

Figure 96: The UK Healthcare Expenditure Per Capita in USD, 2005-2011

Figure 97: Research and Development Expenditure on Pharmaceuticals in USD Million, 2005-2011

Figure 98: The UK Ageing Population, 2008-2011

Figure 99: France In-Patients Discharges by Hospitals, 2005-2011

Figure 100: France Healthcare Expenditure Per Capita, 2005-2011

Figure 101: France Ageing Population, 2008-2011

Table 1: Global API Market Segmentation by Pharmaceutical Raw Materials for Own Needs and Commodity Bulk Drugs Sales on the Basis of Revenue in Percentage (%), 2005-2011

Table 2: Global Commodity Bulk Drugs Market Size by North America, Asia-Pacific Western Europe and Others on the Basis of Revenue in USD Million, 2005-2011

Table 3: Revenue of Top Global API Companies in USD Million, 2009 & 2011

Table 4: Cause and Effect Relationship Analysis between Industry Factors and Expected Prospects of Global API Industry

Table 5: Pfizer Product Pipeline by Phase 1, Phase 2, Phase 3 and Registration, 2012

Table 6: GSK Research and Development Investment allocation by Pharmaceuticals, Vaccines, Healthcare and Major Restructuring in USD Million, 2011

Table 7: Roche Pharmaceutical Clinical Development Projects by New Molecular Entities and Line Extensions in Phase 1, Phase 2 and Phase 3 and Registration, 2011

Table 8: Global HPAPI Market Segmentation by North America, Europe, Asia-Pacific and Others on the Basis of Revenue in USD Million, 2005-2011

Table 9: Global HPAPI Market Future Projections by North America, Europe and Asia-Pacific Market Size Projections by Revenue in USD Million, 2012-2016

Table 10: North America HPAPI Market Size by the US and Canada on the Basis of Revenue in USD Million, 2005-2011

Table 11: North America HPAPI Market Projections by the US and Canada on the Basis of Revenue in USD Million, 2012-2016

Table 12: Europe  HPAPI Market Size by the UK, Germany, France and Others on the Basis of Revenue in USD Million, 2005-2011

Table 13: Europe HPAPI Market Projections by the UK, Germany, France and Others on the Basis of Revenue in USD Million, 2012-2016

Table 14: Asia-Pacific HPAPI Market Size by Japan, China, India and Others on the Basis of Revenue in USD Million, 2005-2011

Table 15: Asia-Pacific HPAPI Market Projections by Japan, China, India and Others on the Basis of Revenue in USD Million, 2012-2016

Table 16: Correlation Matrix of Germany HPAPI Market

Table 17: Regression Coefficients Output

License Type Excel Only Single User Single User + Excel Hard Copy Corporate User License
User Sharing Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only. Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only. Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only. Access to Printed Report; No Soft Copy Multiple Users within the Company/ Enterprise
Print Option
Copy Option :Yes :No
Citation Yes (Not Publically; but to Private Parties within the company/ affiliate)
Deliverable Format :via Email :via Email ; :via Email Printed Publication/ Book by Post ; :via Email
Customization 20%
Analyst Time (Post Purchase Queries on Call/ Email)
Disclaimer : In no circumstance, the complete / part of the publication may be resold for monetary terms by the client or any other party related to the client or can be made available on third party website or on Google for general public view.
To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Pfizer Inc, Glaxo Smithkline Pharmaceuticals Ltd, Roche, Astra Zeneca, Novartis

API, HPAPI, Generic API, Innovator API, Synthetic Product Type Route, Biotechnology based API, Commodity Bulk Drugs

select a license
Single User License
USD 960 INR 66038
Hard Copy License
USD 1280 INR 88051
Corporate User License
USD 1720 INR 118319

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com